Department of Internal Medicine, Division of Hematology and Oncology, Henry Ford Health System, Detroit, Michigan, USA.
Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cancer Invest. 2023 Jan;41(1):12-24. doi: 10.1080/07357907.2022.2119479. Epub 2022 Dec 12.
The therapeutic landscape of lung cancer treatment is changing rapidly, and new data was presented at the recently concluded American Society of Clinical Oncology 2022 (ASCO22) meeting. We highlight studies of clinical relevance that represent significant updates in the current management of non-small cell lung cancer (SCLC) and small cell lung cancer (NSCLC). We summarize the updates in early-stage NSCLC, mutated and non-mutated advanced NSCLC as well as small cell lung cancer (SCLC), and discuss these advances in the context of the current clinical standard of care.
肺癌治疗的治疗领域正在迅速变化，最近举行的美国临床肿瘤学会 2022 年（ASCO22）会议上提出了新的数据。我们重点介绍了具有临床相关性的研究，这些研究代表了非小细胞肺癌（SCLC）和小细胞肺癌（NSCLC）当前管理方面的重大更新。我们总结了早期非小细胞肺癌、突变和非突变晚期非小细胞肺癌以及小细胞肺癌的最新进展，并根据当前的临床护理标准讨论了这些进展。
Cancer Invest. 2023-1
Radiol Clin North Am. 2012-9
J Clin Oncol. 2014-2-24
Nihon Rinsho. 2010-6
Zhongguo Fei Ai Za Zhi. 2020-3-20
Am Soc Clin Oncol Educ Book. 2021-3
FP Essent. 2018-1
MedComm (2020). 2025-6-27
Technol Cancer Res Treat. 2025
Zotero 插件